Condition: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia, Refractory · Refractory/Relapse Acute Myeloid Leukemia · Sponsor: Keystone Nano, Inc
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
This description comes directly from the study's public registry record.
James H Adair, Ph.D. · 814-360-4654 · jadair@pendreabio.com
Bernadette M Adair, BS · ba8387@gmail.com
Always discuss trial participation with your own doctor first.
| University of Virginia Cancer Center | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04716452